Bullous PemphigoidMANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

518 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp31

Immediate priorities

›Life-threatening presentations requiring urgent action

›Extensive skin loss with systemic infection signs

›Fever, tachycardia, hypotension suggesting sepsis

›Sepsis is the leading cause of death in bullous pemphigoid

›Hemodynamic instability from secondary infection

›SBP < 90 mmHg or MAP < 65 mmHg

›Initiate sepsis bundle: IV fluids, blood cultures, broad-spectrum antibiotics within 1 hour

›Airway compromise from extensive oropharyngeal involvement

›Rare but can occur with severe mucosal disease

›Escalate to critical care if oropharyngeal edema or stridor

Monitoring and targets

›Monitoring priorities in severe or hospitalized BP

›Blister count trend

›>10 new blisters per day defines extensive disease

›Track daily to gauge treatment response

›Infection surveillance

›Daily wound assessment for erythema, purulence, odor

›Temperature and white cell count trend

›Treatment toxicity monitoring

›Blood glucose twice daily on systemic corticosteroids

›Blood pressure monitoring

›Electrolytes every 48 to 72 hours if hypokalemia risk

Escalation triggers and consults

›Escalation and consultation indications

›Dermatology — all confirmed or suspected cases

›Skin biopsy and direct immunofluorescence required for definitive diagnosis

›Urgent if diagnosis uncertain or disease rapidly progressive

02History/hx50

Symptom onset and character

›Pruritus as the cardinal early symptom

›Often precedes blisters by weeks to months

›Severe, intractable pruritus even before visible blisters

›Nonbullous prodromal phase occurs in more than 20% of patients

›Blister characterization

›Tense dome-shaped bullae on erythematous or normal skin

›Arising on flexural surfaces, trunk, groin, inner thighs

›New blister count per day for severity grading

›Fewer than 10 new blisters per day: moderate disease

›More than 10 new blisters per day: extensive disease

Medication history

›Drug triggers requiring review and potential discontinuation

›DPP-4 inhibitors (gliptins): strongest evidence

›Vildagliptin, linagliptin, sitagliptin — odds ratio approximately 2 to 4

›HLA-DQA1*05 allele associated with DPP-4 inhibitor-induced BP

›Immune checkpoint inhibitors

›PD-1 and PD-L1 inhibitors: nivolumab, pembrolizumab

›Usually occurs weeks to months after initiation

›Loop diuretics and aldosterone antagonists

›Furosemide, spironolactone — reported associations

›Neuroleptics and antipsychotics

›Penicillins and derivatives

Risk factors

›Demographic and comorbid risk factors

›Age >70 years: strongest demographic risk factor

›Incidence rises sharply after age 70

›Institutionalized elderly at highest risk

03Physical Exam/exam30

Skin examination

›Blister morphology and distribution

›Tense dome-shaped bullae 1 to 3 cm on erythematous or normal skin

›Flexural predilection: inner thighs, axillae, groins, abdomen

›Generalized distribution in severe disease

›Urticarial plaques, eczematous patches, excoriations in prodromal phase

›Nikolsky sign

›Negative in bullous pemphigoid

›Positive Nikolsky sign suggests pemphigus vulgaris instead

›Erosions and complications

›Erosions with serous or hemorrhagic crusting at sites of ruptured bullae

›Signs of secondary infection: erythema, warmth, purulence, malodor

›No scarring or milia (distinguishes BP from epidermolysis bullosa acquisita and cicatricial pemphigoid)

Mucosal examination

›Oral and conjunctival assessment

›Oral mucosa: blistering, erosions, white plaques

›Conjunctival injection, symblepharon, or scarring (ocular mucous membrane pemphigoid risk)

›Genital mucosa involvement

›Mucosal predominance should shift differential toward mucous membrane pemphigoid

Vitals and general assessment

›Severity and systemic involvement markers

›Temperature: fever suggests secondary infection or sepsis

›Heart rate and blood pressure: hemodynamic compromise with extensive disease or sepsis

›Blister count documentation: fewer than or more than 10 new blisters per day

›Overall body surface area involvement estimate

PITFALLS

›Common diagnostic errors

›Nonbullous prodromal phase misdiagnosed as eczema, urticaria, or scabies

04Differential Diagnosis/ddx35

Autoimmune blistering diseases

›Primary differentials within pemphigoid group

›Pemphigus vulgaris (ICD-10 L10.0)

›Flaccid blisters, positive Nikolsky sign

›Mucosal predominance (often oral first presentation)

›Intraepidermal acantholysis on histology

›Anti-desmoglein 1 and 3 antibodies

›Mucous membrane pemphigoid (ICD-10 L12.1)

›Mucosal predominance with scarring

›Ocular, oral, genital, laryngeal involvement

›Risk of blindness from conjunctival scarring

›Epidermolysis bullosa acquisita (ICD-10 Q81.9)

›Acral and mechanically induced blisters

›Scarring and milia formation

›Dermal-side IgG binding on salt-split skin (versus epidermal side in BP)

›Linear IgA bullous dermatosis (ICD-10 L13.8)

›String of pearls blister pattern

›IgA deposits on direct immunofluorescence

›Often drug-induced (vancomycin most common trigger)

Other blistering conditions

›Inflammatory and infectious mimics

›Dermatitis herpetiformis (ICD-10 L13.0)

›Grouped vesicles on extensor surfaces

›Granular IgA in dermal papillae

›Celiac disease association

›Scabies with secondary bullae

›Common misdiagnosis in institutionalized elderly

›Burrows, interdigital distribution, contact history

05Laboratory Tests/lt30

Serologic diagnostic tests

›Anti-BP180 NC16A ELISA

›Pooled sensitivity approximately 82%, specificity approximately 94%

›Most clinically useful serologic test for diagnosis

›Levels correlate with disease activity and relapse risk

›High levels at planned treatment discontinuation predict relapse

›Anti-BP230 ELISA

›Lower sensitivity approximately 59%, specificity approximately 95%

›Best used as adjunctive or confirmatory test

›Combined BP180 plus BP230 ELISA sensitivity reaches approximately 90%

›Total serum IgE

›Frequently elevated in BP

›Not diagnostic alone but supports clinical picture

Baseline and monitoring labs

›Pre-treatment baseline panel

›Complete blood count

›Peripheral eosinophilia common and supportive of diagnosis

›Leukocytosis if secondary infection present

›Comprehensive metabolic panel

›Baseline glucose and HbA1c before corticosteroid initiation

›Renal function affects choice of steroid-sparing agents

›Hepatic panel before immunosuppressive agent initiation

›TPMT enzyme activity if azathioprine is planned

›Deficiency predicts severe azathioprine toxicity

›Required before initiating azathioprine

Infection workup

›Secondary infection evaluation

›Wound culture and sensitivity if purulence or malodor

06Diagnostic Tests/dt56

Scoring Systems

›Bullous Pemphigoid Disease Area Index (BPDAI)

›Validated severity scoring tool for BP

›Scores bullae, urticarial lesions, and erosions separately on skin and mucosae

›Score 0 to 360 total

›Used to track treatment response in clinical trials

›Not widely used in emergency settings but relevant for specialist follow-up

›Severity classification for treatment decisions

›Mild: localized disease, manageable pruritus, fewer than 10 new blisters per day

›Topical high-potency corticosteroids adequate

›Moderate: up to 10 new blisters per day

›Systemic therapy or whole-body topical clobetasol considered

›Extensive or severe: more than 10 new blisters per day

›Systemic corticosteroids or whole-body clobetasol propionate 40 g per day required

MRI

›MRI role in bullous pemphigoid

›Not a primary diagnostic modality for BP itself

›No established MRI protocol for BP diagnosis

›Skin biopsy and immunofluorescence are gold standard

›Brain MRI indications

›New neurological symptoms requiring evaluation (stroke, dementia workup)

›BP has strong associations with stroke (OR 2.7), dementia, Parkinson disease

›Contraindications

›Hemodynamically unstable patient

›Non-MRI-compatible implants

›CT imaging in BP management

›CT chest indications

07Disposition/dispo28

Admission indications

›Inpatient admission criteria

›Extensive disease with inability to manage wound care at home

›More than 10 new blisters per day

›Greater than 30% body surface area involvement

›Secondary infection with systemic signs

›Fever, tachycardia, leukocytosis, hemodynamic instability

›Sepsis requiring IV antibiotics

›Frail elderly or patients with dementia without adequate caregiver support

›Cannot apply topical medications independently

›Nutritional compromise from extensive skin erosions

›Initiation of systemic immunosuppression requiring monitoring

›High-dose systemic corticosteroids in patients with significant comorbidities

›Rituximab or IVIG infusion

›Fluid or electrolyte imbalance from extensive skin involvement

Discharge criteria

›Safe outpatient management criteria

›Mild to moderate disease with accessible skin involvement

›Fewer than 10 new blisters per day

›Wound care feasible at home with caregiver or community nursing

›Stable on oral treatment regimen

›Doxycycline 200 mg daily, topical clobetasol, or oral prednisolone

›Adequate support system and functional capacity

›Caregiver available for topical medication application if needed

›Dermatology follow-up arranged within 1 to 2 weeks for biopsy results and treatment adjustment

Transfer and specialist referral

›Specialist consultation requirements

›Dermatology: all confirmed or suspected cases for biopsy, DIF, and ongoing management

08Treatment/t91

Wound care and supportive measures

›Local wound management

›Gentle cleansing with mild soap or saline

›Daily wound care to reduce infection risk

›Non-adherent dressings over erosions

›Blister management technique

›Large tense bullae: lance with sterile technique

›Leave blister roof intact to protect underlying dermis

›Antihistamines for pruritus control

›Cetirizine 10 mg orally once daily

›Hydroxyzine 25 mg orally every 6 to 8 hours (use with caution in elderly)

Topical corticosteroids

›Clobetasol propionate 0.05% — first-line therapy

›Localized or mild disease

›Apply twice daily to active lesions

›Taper frequency as lesions resolve

›Moderate disease: whole-body clobetasol propionate

›10 to 30 g per day initial dose

›Taper over approximately 4 months as disease controlled

›Extensive or severe disease: whole-body clobetasol propionate

›40 g per day initial dose

›Taper over approximately 12 months

›Safer than equivalent systemic corticosteroid doses in elderly

›Class I evidence base for efficacy in BP (Cochrane 2023)

Systemic corticosteroids

›Oral prednisolone — first-line systemic option

›Standard dosing

›0.5 mg per kg per day orally

›Doses above 0.75 mg per kg per day offer no additional benefit

›Higher doses associated with increased mortality in elderly patients

›Taper schedule

›Begin taper once no new blisters for 2 to 3 weeks

›Slow taper over 6 to 12 months depending on disease activity

›Monitor anti-BP180 levels to guide taper — elevated levels predict relapse

›Corticosteroid toxicity prevention

›Calcium 1000 to 1500 mg per day and vitamin D 800 IU per day supplementation

›Proton pump inhibitor for GI protection if high risk

›Bone density monitoring if prolonged therapy

Doxycycline — preferred in frail elderly

›Doxycycline 200 mg per day orally

›Non-inferior to prednisolone for blister control in randomized controlled trial (Williams et al. Lancet 2017)

›Significantly fewer serious adverse events than prednisolone

›Preferred in frail elderly patients with multiple comorbidities

›Mechanism: anti-inflammatory and anti-blister properties via matrix metalloproteinase inhibition

›Duration: continue until blister control achieved then taper

›Contraindications

›Avoid in pregnancy and children under 8 years

›Photosensitivity counseling required

Steroid-sparing immunosuppressive agents

›Azathioprine

›Dosing: 1 to 3 mg per kg per day orally

›Start at 50 mg per day and titrate based on tolerance

›Requires TPMT testing before initiation

›Monitoring: CBC and LFTs every 1 to 3 months

›Onset of action: 4 to 8 weeks

›Mycophenolate mofetil

›Dosing: 1000 to 1500 mg orally twice daily

›Alternative to azathioprine as steroid-sparing agent

›Avoid in pregnancy (teratogenic)

›Monitoring: CBC and renal function monthly

›Methotrexate

›Dosing: 5 to 15 mg orally once weekly

›Folic acid 1 mg per day supplementation required

›Monitoring: CBC, LFTs, and creatinine every 4 to 8 weeks

›Dapsone

›Dosing: 50 to 100 mg orally once daily

›G6PD testing required before initiation

›Risk of hemolytic anemia and methemoglobinemia

Biologics and advanced therapies

›Dupilumab — FDA-approved for BP in adults

›Dosing: 300 mg subcutaneously every 2 weeks (after 600 mg loading dose)

›IL-4 and IL-13 receptor antagonist

›Approved for BP in adults based on randomized controlled trial data (2023)

›Consider in moderate-to-severe BP with inadequate response to conventional therapy

›Generally well tolerated; injection site reactions and conjunctivitis possible

›Rituximab

›Dosing: 1000 mg IV infusion twice, 2 weeks apart (rheumatoid arthritis protocol)

›Or 375 mg per m2 IV weekly for 4 weeks (lymphoma protocol)

›Pre-medicate with methylprednisolone, acetaminophen, antihistamine

›Used for refractory BP or as corticosteroid-sparing in high-risk patients

›Infusion reaction monitoring required

›Omalizumab

›Anti-IgE monoclonal antibody

›Dosing based on IgE levels and body weight per approved dosing table

›Option for refractory BP with elevated total IgE

›IVIG

›Dosing: 2 g per kg per cycle over 2 to 5 days monthly

›Reserved for severe refractory cases

›Pre-infusion IgA level to rule out IgA deficiency

Antibiotic therapy for secondary infection

›Secondary wound infection management

›Mild local infection: topical antimicrobial (mupirocin) plus wound care

›Moderate to severe cellulitis or sepsis

›Cephalexin 500 mg orally every 6 hours for mild cellulitis if outpatient

›Cefazolin 1 to 2 g IV every 8 hours for moderate inpatient cellulitis

›Vancomycin 15 to 20 mg per kg IV every 8 to 12 hours for MRSA coverage when indicated

›AUC-guided monitoring per institutional protocol

›Duration guided by clinical response and culture results

09Special Populations/sp51

Pregnancy

›Gestational considerations for bullous pemphigoid

›BP rare in pregnancy; differentiate from pemphigoid gestationis

›Pemphigoid gestationis: pregnancy-specific, anti-BP180 antibodies, begins periumbilically

›True BP in pregnancy is extremely uncommon

›Medication safety in pregnancy

›Doxycycline contraindicated (tooth discoloration and bone growth effects in fetus)

›Mycophenolate mofetil contraindicated (teratogenic — Category X)

›Methotrexate contraindicated (teratogenic)

›Azathioprine: relatively safer option under specialist guidance if necessary

›Topical clobetasol: use with caution, limit body surface area covered

›Preferred treatment approach in pregnancy

›Topical high-potency steroids for localized disease

›Low-dose oral prednisolone for systemic therapy if required

›Maternal oxygenation and nutritional status monitoring

›Fetal monitoring

›Neonatal skin examination — maternal autoantibodies can cross placenta

›Obstetric collaboration for delivery planning

Geriatric

›Older adult specific considerations

›BP is predominantly a disease of patients over 70 years

›Incidence 21 to 30 per 100,000 person-years in those over 80

›One-year mortality 20 to 40%, approximately 2 to 3 times higher than age-matched controls

›Treatment selection priorities

›Prefer topical clobetasol propionate or doxycycline over systemic corticosteroids when possible

›Oral prednisolone greater than 0.5 mg per kg per day associated with increased mortality in elderly

›Doxycycline 200 mg per day: comparable blister control with significantly fewer serious adverse events

›Corticosteroid toxicity risks in elderly

10Background/b56

Epidemiology

›Incidence and prevalence

›Most common autoimmune subepidermal blistering disease worldwide

›Incidence 2.5 to 42.8 per million population per year (wide geographic variation)

›Rising incidence over past decades — partly attributed to aging population and increased DPP-4 inhibitor use

›Age and sex distribution

›Predominantly affects adults over 70 years

›Incidence increases sharply after age 70

›Slight male predominance in most studies

›Mortality

›One-year mortality 20 to 40%

›Mortality approximately 2 to 3 times higher than age-matched controls

›Leading causes of death: secondary infection (pneumonia, sepsis), cardiovascular events

›Treatment-related adverse effects contribute significantly to morbidity and mortality

›Comorbidity associations

›Neurological diseases: dementia, Parkinson disease, stroke, epilepsy, MS — strong and consistent associations

›Cardiovascular disease risk elevated

›Three times higher pneumonia risk than age-matched controls

Pathophysiology

›Autoimmune mechanisms

›Autoantibodies target hemidesmosomal proteins at the dermal-epidermal junction

›BP180 (type XVII collagen, BPAG2): primary pathogenic target

›BP230 (dystonin, BPAG1): secondary target, cytoplasmic hemidesmosomal protein

›IgG autoantibodies activate complement and recruit eosinophils and neutrophils

›Tissue destruction cascade

›IgG binding to BP180 NC16A domain triggers complement activation

›Eosinophil and mast cell degranulation releases proteases

›Matrix metalloproteinases cleave the basement membrane zone

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Wound care at home

›Gentle cleaning of skin with mild soap and water once daily

›Apply non-stick dressings to open erosions

›If a blister is large and painful, a nurse or doctor can drain it safely — do not tear off the skin over the blister

›Apply prescribed topical clobetasol cream to active blistering areas as directed

›Medications

›Take all prescribed medications as directed

›Do not stop corticosteroids or doxycycline without speaking to your doctor first

›If you are on prednisone, take it with food to reduce stomach upset

›Take calcium and vitamin D supplements daily if prescribed

›Skin protection tips

›Wear soft, loose-fitting clothing to avoid friction on fragile skin

›Avoid scratching — antihistamine medication can help with itching

›Keep skin moisturized with fragrance-free emollient

›Protect skin from sun exposure if on doxycycline (causes photosensitivity)

›Blood sugar monitoring if on prednisone

›Check blood sugar as directed if you have diabetes or are at risk

›Report high readings to your doctor promptly

›Warning signs to return to the emergency department

›Sudden worsening with many new blisters appearing daily

›Skin becoming red, warm, swollen, with pus or foul odor (infection)

›Fever above 38.5 degrees Celsius

›Difficulty breathing or chest pain

›Confusion, severe agitation, or sudden change in mental status

›Inability to eat or drink due to mouth sores

›Blood in stool or vomit (possible steroid-related GI bleeding)

›Falls or suspected fracture (steroid-related bone fragility)

12References/r28

Guidelines and key sources

›Primary guidelines and society recommendations

›European Dermatology Forum guidelines for bullous pemphigoid management

›British Association of Dermatologists guidelines for BP

›Cochrane systematic review: Singh et al. Interventions for bullous pemphigoid (2023)

›Williams HC et al. Doxycycline versus prednisolone for BP — Lancet 2017 RCT

›Key diagnostic studies

›Grochowska-Rak et al. BP180 and BP230 ELISA meta-analysis — International Journal of Dermatology 2025

›Anti-BP180 sensitivity 82%, specificity 94%

›Combined ELISA sensitivity reaches 90%

›Sardy et al. DIF versus ELISA comparison — JAAD 2013

›DIF gold standard: sensitivity 91%, specificity 98%

›Meijer et al. Diagnostic strategy for BP variants — JAMA Dermatology 2019

Drug association and special population references

›Drug-induced BP evidence

›Liu et al. Medication association systematic review and meta-analysis — JAMA Dermatology 2020

›DPP-4 inhibitor association: odds ratio approximately 2 to 4

›Asdourian et al. Checkpoint inhibitor-associated BP — JAMA Dermatology 2022

›Ozeki et al. HLA-DQA1 variants and DPP-4 inhibitor-induced BP — Journal of Investigative Dermatology 2023

›Neurological associations and outcomes

›Lai YC et al. BP and neurological diseases meta-analysis — JEADV 2016

›Dementia OR 4 to 5, Parkinson OR approximately 3, stroke OR 2.7

›Shen et al. Mortality risk in BP — JAMA Dermatology 2022

›One-year mortality 20 to 40%, 2 to 3 times higher than age-matched controls

›Akbarialiabad et al. Bullous Pemphigoid review — Nature Reviews Disease Primers 2025

›Coding reference

›ICD-10 L12.0 bullous pemphigoid

›ICD-10 L12.1 cicatricial pemphigoid

Learn More: Bullous Pemphigoid→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.